| Literature DB >> 25642394 |
Travis M Cruickshank1, Jennifer A Thompson1, Juan F Domínguez D2, Alvaro P Reyes1, Mike Bynevelt3, Nellie Georgiou-Karistianis2, Roger A Barker4, Mel R Ziman5.
Abstract
BACKGROUND: There is a wealth of evidence detailing gray matter degeneration and loss of cognitive function over time in individuals with Huntington's disease (HD). Efforts to attenuate disease-related brain and cognitive changes have been unsuccessful to date. Multidisciplinary rehabilitation, comprising motor and cognitive intervention, has been shown to positively impact on functional capacity, depression, quality of life and some aspects of cognition in individuals with HD. This exploratory study aimed to evaluate, for the first time, whether multidisciplinary rehabilitation can slow further deterioration of disease-related brain changes and related cognitive deficits in individuals with manifest HD.Entities:
Keywords: Cognition; Huntington's disease; executive function; neuropathology; rehabilitation
Mesh:
Year: 2015 PMID: 25642394 PMCID: PMC4309878 DOI: 10.1002/brb3.312
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Participant demographics
| No | Gender | CAG length | Age | Disease Duration (Years) | DBS | UHDRS-TMS | Medication (baseline) | Medication (during) |
|---|---|---|---|---|---|---|---|---|
| 1 | Male | 46 | 57 | 7.6 | 596 | 45 | Aripiprazole, Mirtazapine, Escitalopram | Aripiprazole Escitalopram |
| 2 | Male | 42 | 71 | 9.5 | 461.5 | 59 | Clonazepam, OlanzapineAmantadine, Mirtazapine | Clonazepam, OlanzapineAmantadine, Mirtazapine |
| 3 | Female | 46 | 51 | 2.3 | 535.5 | 18 | Venlafaxine, Mirtazapine, Olanzapine | Setraline, Creatine, CoQ10, Venlafaxine, Mirtazapine, Olanzapine |
| 4 | Male | 45 | 47 | 1.8 | 446.5 | 52 | Aripiprazole, Olanzapine, Mirtazapine, Escitalopram, Nitrazepam | Aripiprazole, Olanzapine, Mirtazapine, Escitalopram, Nitrazepam, Benzhexol |
| 5 | Female | 46 | 45 | 4.2 | 472.5 | 36 | Olanzapine, Escitalopram, CoQ10 | Olanzapine, Escitalopram, CoQ10 |
| 6 | Female | 44 | 54 | 0.9 | 459 | 19 | – | Olanzapine, Escitalopram |
| 7 | Female | 41 | 50 | 0.6 | 275 | 25 | Mirtazapine, Escitalopram, Aripiprazole, Lorazepam | Mirtazapine, Escitalopram, Aripiprazole, Lorazepam, Tetrabenazine, Propranolol |
| 8 | Male | 44 | 48 | 1.4 | 408 | 58 | Aripiprazole, Gabapentin, Escitalopram, Olanzapine | Amantadine, Clonazepam, Amantadine, Gabapentin, Pramipexole |
| 9 | Female | 44 | 50 | 10.5 | 433.5 | 44 | Tetrabenazine | Fluoxetine, Tetrabenazine, Actonel |
| 10 | Female | 39 | 49 | 3.3 | 175 | 39 | – | – |
| 11 | Male | 41 | 61 | 0.9 | 335.5 | 13 | – | – |
| 12 | Female | 43 | 56 | 1.4 | 427.5 | 32 | Haloperidol, Paroxetine | Haloperidol, Paroxetine |
| 13 | Male | 41 | 53 | 17.3 | 297 | 5 | CoQ10 | CoQ10 |
| 14 | Male | 44 | 48 | 1 | 408 | 12 | Escitalopram | Aripiprazole, Escitalopram |
| 15 | Male | 40 | 68 | 6.7 | 310.5 | 17 | Prazosin | Aripiprazole, Atenolol, Atorvastatin, Clonazepam, Clopidogrel, Quetiapine, |
| Summary | 8M/7F | 43.6 ± 2.2 | 52.5 ± 6.6 | 4.6 ± 4.8 | 402.7 ± 107.7 | 31.6 ± 17.5 | NA | NA |
DBS, Disease Burden Score (age × [CAG−35.5]), UHDRS-TMS, Unified Huntington's Disease Rating Scale-Total Motor Score.
Figure 1Significant GM volume changes after multidisciplinary rehabilitation in individuals with manifest HD (A) Significantly increased GM volume in the DLPFC and right caudate nucleus tail after 9 months of multidisciplinary rehabilitation in individuals with HD (red-yellow), and a significant correlation between increased GM volume in DLPFC and preserved performance on the RDI task (green). Results are displayed on the study-specific template normalized to MNI space (P < 0.05, uncorrected). (B) Scatterplot illustrating the correlation between increased DLPFC volume at the peak voxel and preserved performance on the RDI task.
Figure 2Whole brain GM volume changes in individuals with manifest HD Results of the VBM analysis beyond the ROIs after 9 months of multidisciplinary rehabilitation. GM volume loss in blue; GM volume increases in red-yellow. Results are displayed on the study-specific template normalized to MNI space (P < 0.01, uncorrected).
Changes in cognitive function after 9 months of multidisciplinary rehabilitation in individuals with manifest HD
| Outcome measures | Baseline ( | Post-trial ( | |
|---|---|---|---|
| CWIT | |||
| Color naming | 48.35 ± 18.86 | 52.35 ± 22.57 | 0.0999 |
| Word reading | 34.00 ± 10.97 | 35.35 ± 9.77 | 0.3249 |
| Inhibition | 91.00 ± 39.25 | 93.57 ± 41.39 | 0.4525 |
| TMT | |||
| Visual scanning | 38.76 ± 15.76 | 43.52 ± 15.98 | 0.1149 |
| Number sequencing | 55.73 ± 19.87 | 61.80 ± 23.49 | 0.0507 |
| Letter sequencing | 61.92 ± 34.05 | 66.21 ± 30.77 | 0.1262 |
| Motor speed | 58.75 ± 27.39 | 62.31 ± 25.90 | 0.2433 |
| HVLT-R | |||
| Free recall | 17.66 ± 5.56 | 16.73 ± 6.21 | 0.2019 |
| Delayed recall | 4.92 ± 2.36 | 6.28 ± 3.14 | 0.0130 |
| Retention | 76.16 ± 29.21 | 81.22 ± 27.32 | 0.1866 |
| Recognition | 8.06 ± 3.08 | 8.93 ± 2.34 | 0.0793 |
| SDMT | |||
| Correct written | 27.00 ± 10.25 | 26.78 ± 9.96 | 0.4525 |
| Correct oral | 31.00 ± 14.17 | 28.46 ± 15.59 | 0.1374 |
CWIT, Color Word Interference Test; TMT, Trail Making Trials; HVLT-R, Hopkins Verbal Learning Test-Revised; SDMT, Symbol Digits Modalities Test. Significance was set at *P < 0.05.